Stay updated on Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page
- Check3 days agoChange DetectedThe study status changed from Recruiting to Active, not recruiting. Several study contact details and names were removed from the page.SummaryDifference3%

- Check10 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0; no visible changes to study content.SummaryDifference0.0%

- Check17 days agoChange DetectedThe page revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedRevision: v3.4.2 is now displayed and the prior government funding status notice has been removed. The page’s primary study details and navigation remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check53 days agoChange DetectedNotice added about government funding status and NIH Clinical Center operations (with guidance to opm.gov); page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check60 days agoChange DetectedGlossary visibility was added and UI labels were updated (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'). The page revision was bumped to v3.4.0, replacing the previous wording for these items. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.